Scarica l'app Stockscreener
5.33
0.95%
0.05
Dopo l'orario di chiusura:
5.36
0.03
+0.56%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Verastem Inc Borsa (VSTM) Ultime notizie
Verastem Stock Soars 46% After FDA Grants Priority Review for Cancer Treatment – Market - HPBL
Verastem stock retains Buy rating as KRASG12D program and LGSOC launch gain traction - Investing.com Canada
Verastem, Inc. (NASDAQ:VSTM) Shares Sold by Jane Street Group LLC - Defense World
Verastem Oncology Names Matthew E. Ros as Chief Operating Officer - BioSpace
Verastem Oncology Names Pharma Veteran Matthew Ros as COO Ahead of Key Cancer Drug Launch - StockTitan
Verastem Oncology Appoints Matthew E. Ros as Chief Operating Officer - Marketscreener.com
Dan Paterson Sells 8,568 Shares of Verastem, Inc. (NASDAQ:VSTM) Stock - MarketBeat
Verastem CEO sells shares worth $44,896 By Investing.com - Investing.com Australia
Verastem CEO sells shares worth $44,896 - Investing.com India
Verastem licenses GenFleet's KRAS inhibitor - The Pharma Letter
Verastem Licenses Investigational Cancer Drug VS-7375 from GenFleet, Shares Rise 4.1% – Market - HPBL
Verastem Oncology: $150 Million Credit Facility Deal Signed - Pulse 2.0
Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China - Business Wire
Verastem Oncology announces debt refinancing with Oberland Capital - MSN
Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025 - BioSpace
Royal Bank of Canada Forecasts Strong Price Appreciation for Verastem (NASDAQ:VSTM) Stock - Defense World
FDA reviewing oral combination treatment for ovarian cancer - Myeloma Research News
Follicular Lymphoma Market Expected to rise, 2034 | Epizyme|Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, Bristol-Myers-Squibb, Roche, Incyte Corp - The Globe and Mail
Follicular Lymphoma Market Expected to rise, 2034 | - openPR
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Verastem's SWOT analysis: biotech firm's stock rides on avutometinib approval - Investing.com India
Barclays PLC Has $167,000 Position in Verastem, Inc. (NASDAQ:VSTM) - Defense World
Geode Capital Management LLC Raises Stock Position in Verastem, Inc. (NASDAQ:VSTM) - Defense World
Verastem Oncology Grants Stock Options to New Employee at $6.49 Exercise Price - StockTitan
Chugai Pharmaceutical Co., Ltd.Verastem Oncology's Announcement Regarding Avutometinib - Marketscreener.com
Royal Bank of Canada Issues Positive Forecast for Verastem (NASDAQ:VSTM) Stock Price - MarketBeat
VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag - MSN
Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Rating of “Buy” from Analysts - Defense World
Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Verastem: Planning The PDUFA Run-Up (NASDAQ:VSTM) - Seeking Alpha
State Street Corp Grows Holdings in Verastem, Inc. (NASDAQ:VSTM) - Defense World
Verastem: BLA Acceptance Puts Key Goals In Sight (NASDAQ:VSTM) - Seeking Alpha
Verastem soars on FDA priority review for avutometinib - The Pharma Letter
Verastem stock climbs on raised price target and FDA milestone for KRASm treatment - Investing.com Nigeria
Verastem stock remains volatile but promising data reinforces Buy rating by B.Riley - Investing.com Canada
BTIG Research Issues Positive Forecast for Verastem (NASDAQ:VSTM) Stock Price - Defense World
Verastem Shares Surge Over 24% on FDA Acceptance of Cancer Thera - GuruFocus.com
Verastem Shares Soar on FDA Priority Review of Cancer Treatment - Marketscreener.com
FDA sets priority review date for Verastem’s new ovarian cancer drug - The Business Journals
Regulatory Milestone Sends Verastem (VSTM) Shares Soaring - Stocks Telegraph
Stifel Financial Corp Buys 11,642 Shares of Verastem, Inc. (NASDAQ:VSTM) - Defense World
Verastem Shares Surge Over 24% on FDA Acceptance of Cancer Therapy Application - Yahoo Finance
Verastem (NASDAQ:VSTM) Price Target Raised to $20.00 at BTIG Research - MarketBeat
Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer - BioSpace
Verastem Oncology's New Cancer Treatment Gets FDA Priority Review - Marketscreener.com
FDA accepts Verastem NDA for priority review, stock jumps 20% (update) - Seeking Alpha
0.65%
4.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):